KRAS
Entity.
- Evidence
- 459 documents · 177 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 21 Oct 2026
- Measured
- 9% of mentions say something specific about it; the rest only name it
- As of
- 22 Oct 2026
Where this comes from
- Crc-Digest · 2026-10-21 · AACR Report Highlights KRAS-Targeted Therapies Among Key Advances (opens the source in a new tab)
- Biochim Biophys Acta Mol Cell Biol Lipids · 2026-10-19 · Gossypin suppresses mutant KRAS G12D driven oncogenic and adipogenic activity via NF-κB signaling in pancreatic cancer. (opens the source in a new tab)
- Nature Cancer · 2026-10-19 · Author Correction: Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS (opens the source in a new tab)
- Mutant Tumors] · 2026-10-16 · VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors (opens the source in a new tab)
- STAT · 2026-10-15 · STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer (opens the source in a new tab)
- Cancer Innov · 2026-10-15 · Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management. (opens the source in a new tab)
- Fierce Pharma · 2026-10-15 · Fierce Pharma Asia—Roche’s $1.2B obesity deal; Asahi Kasei’s FDA nod; Verastem’s KRAS boon (opens the source in a new tab)